Stocks and InvestingStocks and Investing
Mon, January 31, 2022
Sun, January 30, 2022
Fri, January 28, 2022
Thu, January 27, 2022

Matthew Taylor Maintained (ABT) at Strong Buy with Increased Target to $142 on, Jan 27th, 2022


Published on 2024-10-27 19:27:04 - WOPRAI, Matthew Taylor
  Print publication without navigation


Matthew Taylor of UBS, Maintained "Abbott Laboratories" (ABT) at Strong Buy with Increased Target from $138 to $142 on, Jan 27th, 2022.

Matthew has made no other calls on ABT in the last 4 months.



There are 10 other peers that have a rating on ABT. Out of the 10 peers that are also analyzing ABT, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Danielle Antalffy of "SVB Leerink" Maintained at Hold with Increased Target to $140 on, Thursday, October 21st, 2021
  • Simon Baker of "Redburn Partners" Initiated at Hold on, Thursday, October 14th, 2021


These are the ratings of the 8 analyists that currently disagree with Matthew


  • Robbie Marcus of "JP Morgan" Maintained at Buy and Held Target at $125 on, Saturday, January 22nd, 2022
  • Joanna Wiensch of "Citigroup" Maintained at Strong Buy with Increased Target to $154 on, Wednesday, December 15th, 2021
  • Shagun Singh of "RBC Capital" Initiated at Buy and Held Target at $146 on, Friday, December 10th, 2021
  • James Mainwaring of "Atlantic Equities" Upgraded from Hold to Buy and Held Target at $144 on, Wednesday, October 27th, 2021
  • Raj Denhoy of "Jefferies" Maintained at Strong Buy with Increased Target to $145 on, Thursday, October 21st, 2021
  • Marie Thibault of "BTIG" Maintained at Strong Buy with Increased Target to $143 on, Wednesday, October 20th, 2021
  • Larry Biegelsen of "Wells Fargo" Maintained at Buy and Held Target at $135 on, Sunday, October 10th, 2021
  • Joshua Jennings of "TD Cowen" Maintained at Buy and Held Target at $140 on, Friday, October 8th, 2021